# Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy

Source: https://onco.cc/ideas/idea-reg-early-apheresis-banking/  
OnCo record `idea-reg-early-apheresis-banking` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

By the time patients need CAR-T their immune cells are often exhausted by earlier treatment. Storing healthy cells early would improve manufacturing success and cut the wait.

## Summary

Manufacturing failures and poor CAR-T fitness are associated with prior lines of chemotherapy, bendamustine exposure and low lymphocyte counts. Collecting and cryopreserving autologous lymphocytes at diagnosis or first relapse for patients with a high probability of later needing CAR-T (high-risk large B-cell lymphoma, high-risk myeloma) would supply fitter starting material and remove apheresis scheduling from the critical path. The proposal is a prospective banking programme with defined eligibility, consent and storage funding, and a regulatory position on the use of banked material.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Patients treated from banked early-collected cells have a manufacturing failure rate below 3% (versus 5-15% from late apheresis), a shorter referral-to-infusion interval by at least ten days, and higher CAR-T expansion and durable response rates.
- Rationale: T-cell fitness is the strongest product-level predictor of CAR-T outcome, and it declines with each line of therapy; banking is routine for stem cells in myeloma and the storage cost is modest relative to the therapy.
- Proposed test: Prospective cohort banking cells in 300 newly diagnosed high-risk lymphoma patients, comparing manufacturing metrics and outcomes for those later needing CAR-T against contemporaneous patients apheresed at relapse.
- Maturity: early-clinical
- Actor: clinic

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- key papers: [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-early-apheresis-banking.json